3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Chewy reported revenue up 7.7% year over year and EPS rising to $0.23 from $0.15, both ahead of estimates, though full-year revenue guidance was cut to $13.4 billion-$13.55 billion from $13.6 billion-$13.75 billion. DraftKings posted 17% revenue growth to $1.65 billion as competitive fears around Kalshi and Polymarket appear less severe than initially feared, while Rocket Lab remains attractive after a pullback of almost 30% from last month's peak. The article is broadly constructive on all three names, but the message is more about long-term stock-picking than a major near-term catalyst.

Analysis

The common thread is that market leadership is being driven less by pristine fundamentals than by narrative compression. Chewy and DraftKings are both being punished for slowing growth at scale, but the important second-order effect is that each is quietly increasing operating leverage: when revenue growth is merely decent, margin expansion can create disproportionate upside to EBITDA and EPS. That makes both names more sensitive to multiple expansion than to near-term top-line surprises, which is why the stocks can rerate sharply on even modest beats or improved guidance cadence.

The competitive take on DraftKings is the more interesting setup. New entrants can skim speculative volume, but they also validate the category and force DraftKings to monetize its brand moat through partnerships, cross-sell, and product bundling. The risk is not immediate share loss; it is regulatory fragmentation and promo intensity if prediction markets keep drifting into adjacent use cases, which could delay margin inflection for 2-4 quarters even if revenue holds up.

Rocket Lab is the cleaner asymmetry. The market keeps anchoring on launch competition, but the larger value driver is the less cyclical satellite-systems business, which should smooth cash generation and reduce dependence on launch cadence. If medium-lift launches become the bigger market as expected, RKLB's Neutron becomes an option on a structurally larger TAM, but the near-term catalyst is execution on testing milestones; any delay would likely hit the stock faster than it would change long-run value. The contrarian miss is that the SpaceX IPO may actually widen investor awareness of the category and eventually create multiple beneficiaries rather than a zero-sum winner-take-all outcome.

Key Decisions for Investors

• Long CHWY on weakness over the next 1-3 months; use a 12-18 month horizon. Risk/reward favors a rerating if autoship penetration keeps rising and the company posts another clean margin beat. Add only if the stock trades at a discount to its own history despite stable gross margin expansion.
• Long DKNG vs short a retail-like consumer discretionary basket for a 3-6 month pair trade. Thesis: DraftKings has more durable pricing power and brand leverage than the market is modeling, while the basket lacks a comparable margin inflection catalyst.
• Buy RKLB with a 6-12 month horizon, but size smaller until Neutron testing milestones are confirmed. Upside is materially larger if the market revalues the satellite-systems revenue stream as the base case; downside is concentrated around launch-delay headlines.
• Use call spreads rather than outright longs in CHWY and DKNG to express upside from multiple expansion while capping duration risk. Best entry is after any post-earnings volatility compression, when implied volatility normalizes.
• Avoid shorting any of the three outright here; the cleaner expression is to short over-owned, high-multiple software or internet names that lack near-term margin leverage if you want a relative-value hedge.